• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Facebook
  • Instagram
  • LinkedIn
  • TikTok
  • Twitter
  • YouTube
CDE Almería – Centro de Documentación Europea – Universidad de Almería

CDE Almería - Centro de Documentación Europea - Universidad de Almería

Centro de Documentación Europea de la Universidad de Almería

  • HOME
  • WHAT´S ON
    • EU NEWS
    • Activities
    • EU Calls and Awards
    • Radio Program «Europe with You»
  • DOCUMENTATION
    • Bibliographic Collection
      • Almería EDC Digital Collection
      • UNIVERSITY OF ALMERIA LIBRARY
    • Documentation by topic
    • EU Media Collection
      • Web Space
      • MEDIATHEQUE REPOSITORY
  • Europe on the net
    • Institutions
    • EU Representation in Spain
    • European information network of Andalusia
  • ABOUT US
    • Presentation
    • People
    • Contact
  • Spanish
  • English

New intraoperative probe for breast cancer tissue

Inicio » EU News » New intraoperative probe for breast cancer tissue

15 de March de 2019

Breast cancer diagnosis has improved over the years, leading to an increasing number of surgical tumour resections in specific breast conservative surgery. An innovative probe for detecting breast cancer tissue during operation could improve retention of healthy tissue and improve local treatment outcome.

As with most cancer operations, breast conserving surgery aims to completely remove cancer with clear surgical margins while maintaining the natural shape of the breast. However, this is not always possible, leading to breast deformity and residual cancer in 20-30 % of patients who require reoperation after a partial mastectomy. Apart from patient dissatisfaction this contributes to increased health care costs and poorer cosmetic results.

An intra-operative probe for cancer tissue

ONCOscanner is an innovative solution that enables intra-operative recognition of collected tissues during surgical removal of cancerous breast tissue. As the coordinator of the EU-funded ONCOscanner project Dr Stanislaw Rogozinski explains, “the ONCOscanner probe supports surgeons by allowing them to assess margins of the breast cancer tissue during operation.″

The ONCOscanner probe has the capacity to identify cancerous tissue during surgery. Through the dielectric technique, it measures the electric conductivity and permeability of normal and malignant tissue. Electric properties are lowest in fat tissue and high in cancerous tissue, allowing the differentiation between healthy and malignant breast tissue.

Importantly, the ONCOscanner probe has been designed to overcome the influence of components with high electrical conductivity such as blood, plasma and electrolytes. It can be used repeatedly during operation without the need of irradiation or special training. The probe has also been validated in many medical experiments and demonstrated absolute safety, very high sensitivity (87 %) and specificity (99 %).

Effective candidate drug combination for treatment of triple negative breast cancer

Most forms of breast cancer express the three target receptors ER, PR and HER2, and as such have more sustainable therapies. TNBC is difficult to treat successfully. Aptly named due to the lack of these three targetable receptors, the mainstay practice for TNBC in the clinic is to treat with non-targeted cytotoxic chemotherapies.

Researchers with the EU-funded TRIPLECON project have already discovered with the aid of a European Research Council advanced grant that an inhibitor targeting cyclin-dependent kinase 9 (CDK9) strikingly synergises with drugs targeting the EGFR receptor family. This signals inhibition of cell proliferation of TNBC cell lines and directs these cells towards programmed cell death, apoptosis.

The overall goal of the TRIPLECON project was to “exploit this novel finding and provide proof-of-concept (PoC) evidence that stalling CDK9 signalling may enable successful targeted combination therapy in TNBC,” outlines Prof. John Martens of project coordinator Erasmus University Medical Center, Rotterdam. The research team used TNBC patient-derived xenograft (PDX) mouse models in vivo to test the safety of the new synergistic treatment.

More Information

Full news “intraoperative probe for breast cancer tissue”

Full news “rug combination for treatment of triple negative breast cancer”

Publicaciones relacionadas:

Imminent anti-metastatic vaccine for prostate cancer New technology is recognising affective states €2 billion to fast forward the creation of the European Innovation Council Epigenetic therapy! Switching off your own cancer genes R&I cooperation between EU and Middle East reaches new heights

“This is a space for debate. All comments, for or against publication, that are respectful and do not contain expressions that are discriminatory, defamatory or contrary to current legislation will be published”.

Reader Interactions

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Primary Sidebar

Publicaciones relacionadas

Imminent anti-metastatic vaccine for prostate cancer New technology is recognising affective states €2 billion to fast forward the creation of the European Innovation Council Epigenetic therapy! Switching off your own cancer genes R&I cooperation between EU and Middle East reaches new heights

Footer

Logotipo en negativo del Centro de Documentación Europea de Almería
  • CDE Almería
  • Edificio Parque Científico-Tecnológico (Pita)
  • Planta: 1ª, Despacho: 2904120.
  • Ctra. Sacramento s/n. Almería (Spain)
  • Teléfono: (+34) 950 015266

HOME
NEWS
DOCUMENTATION
EUROPE ON THE NET
ABOUT US

  • LEGAL NOTICE
  • PRIVACY POLICY
  • COOKIE POLICY
  • ACCESSIBILITY
  • SITEMAP

Copyright © 2023 CDE Almería · Creative Commons LicenseThis work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

<p>El Centro de Documentación Europea de la Universidad de Almería utiliza cookies propias y de terceros para facilitar al usuario la navegación en su página Web y el acceso a los distintos contenidos alojados en la misma. Asimismo, se utilizan cookies analíticas de terceros para medir la interacción de los usuarios con el sitio Web. Pinche el siguiente enlace si desea información sobre el uso de cookies y como deshabilitarlas. ajustes</p>

Politica de privacidad

El Centro de Documentación Europea de la Universidad de Almería utiliza cookies propias y de terceros para facilitar al usuario la navegación en su página Web y el acceso a los distintos contenidos alojados en la misma. Asimismo, se utilizan cookies analíticas de terceros para medir la interacción de los usuarios con el sitio Web. Pinche el siguiente enlace si desea información sobre el uso de cookies y como deshabilitarlas. <a href="/politica-de-cookies" rel="noopener" target="_blank">Más información</a>

Cookies estrictamente necesarias

Las cookies estrictamente necesarias tiene que activarse siempre para que podamos guardar tus preferencias de ajustes de cookies.

Básicamente la web no funcionara bien si no las activas.

Estas cookies son:

  • Comprobación de inicio de sesión.
  • Cookies de seguridad.
  • Aceptación/rechazo previo de cookies.

Si desactivas esta cookie no podremos guardar tus preferencias. Esto significa que cada vez que visites esta web tendrás que activar o desactivar las cookies de nuevo.

Cookies de terceros

Esta web utiliza Google Analytics, Google Tag Manager y Yandex Metrika para recopilar información anónima tal como el número de visitantes del sitio, o las páginas más populares.

Dejar estas cookies activas nos permite mejorar nuestra web.

¡Por favor, activa primero las cookies estrictamente necesarias para que podamos guardar tus preferencias!

Política de cookies

Pinche el siguiente enlace si desea información sobre el uso de cookies y como deshabilitarlas. Más información